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OBJECTIVES We wished to examine the effects of age and gender on plasma brain natriuretic peptide
(BNP) concentration in a population-based study.
BACKGROUND Measurement of BNP concentration is approved for use in the diagnosis of heart failure and
may aid in the detection of left ventricular dysfunction. Although BNP is approved for
clinical use, there are few data regarding the range of BNP observed in persons without
cardiovascular disease or cardiac dysfunction. These data are essential for the interpre-
tation of BNP.
METHODS In 2,042 randomly selected residents of Olmsted County, Minnesota, 44 years old, BNP
(Shionogi and Biosite assays), Doppler echocardiography, and medical record review were
performed. A normal subset of subjects (n  767) in sinus rhythm without cardiovascular,
renal, or pulmonary disease or diabetes; on no cardiovascular medications; and with normal
systolic, diastolic, and valvular function was identified.
RESULTS Within the normal subset, the distribution of BNP differed by age, gender, and assay system.
With both assays, BNP increased significantly with age and was significantly higher in
women than men, leading to age-, gender-, and assay-specific reference ranges. Receiver
operating characteristic analysis for the ability of BNP to detect an ejection fraction 40%
was performed in each age/gender stratum in the entire cohort (n  2,042) and confirmed
that discriminatory values for BNP for detection of reduced ejection fraction were higher in
women and older persons and were different between the two assays.
CONCLUSIONS Interpretation of BNP should include consideration of age-, gender-, and assay-specific
partition values. (J Am Coll Cardiol 2002;40:976–82) © 2002 by the American College of
Cardiology Foundation
Brain natriuretic peptide (BNP) is a member of the family
of genetically distinct natriuretic peptides synthesized and
released by cardiomyocytes in response to increased trans-
mural wall stress (1). Although this response is critical for
cardiorenal regulation, the increase in plasma BNP concen-
tration has diagnostic implications as well. Indeed, BNP
may be useful for the detection of asymptomatic left
ventricular (LV) dysfunction (2,3) and the diagnosis (4,5)
and management (6) of congestive heart failure (CHF).
Whereas most previous studies have utilized an immunora-
diometric assay (Shionogi), recent Food and Drug Admin-
istration approval of a point-of-care assay (Biosite Triage)
for use in the diagnosis of CHF has made the possibility of
using BNP in clinical practice a reality.
The range of BNP observed in subjects without cardio-
vascular disease or cardiac dysfunction has not been well
established. Although a few studies suggest that age and
gender may influence circulating natriuretic peptide levels
(7–9), the magnitude of these effects and their potential
importance in the interpretation of BNP remains unclear.
Therefore, we measured BNP with two commercially avail-
able assays in a population-based cohort. In subjects without
cardiovascular disease or cardiac dysfunction (n  767), we
assessed the influence of the assay used, age, and gender on
BNP. We evaluated the influence of clinical factors, renal
function, and cardiac structural parameters on BNP, as
age/gender-related changes in these factors could mediate
associations between BNP and age/gender. In the entire
cohort (n  2,042), we determined whether the BNP that
identified subjects having systolic dysfunction (ejection frac-
tion [EF] 40%) with optimal sensitivity and specificity
varied with age, gender, and assay.
METHODS
This study was approved by the Mayo Institutional Review
Board.
Study setting. The characteristics of the Olmsted County,
Minnesota, population and the unique resources for
population-based epidemiologic research in Olmsted
County have been previously described (10,11).
Population sampling, subject recruitment, and enroll-
ment. A random sample of the population 44 years was
invited to participate. A sampling fraction of 7% was applied
within each of the gender and age (five-year) specific strata.
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Of the 4,203 subjects invited, 2,042 (47%) participated.
Analysis of the medical records of 500 nonparticipants
revealed no clinically significant differences between partic-
ipants and nonparticipants. Subjects gave written consent
and underwent echocardiography and phlebotomy.
Of the 2,042 participants, 1,020 had no history of
cardiovascular, renal, or pulmonary disease and were on no
cardiovascular medications. Of these, 75 were excluded
because of an abnormal two-dimensional (2-D) echocardio-
gram, 64 were excluded by an inability to characterize
diastolic function, and 114 had abnormal diastolic function.
Thus, 767 subjects had normal EF (50%), no wall motion
abnormalities, normal diastolic function, no valve disease,
and normal sinus rhythm; these make up the normal
subgroup. The criteria used to establish the normal sub-
group resulted in small numbers in the oldest (age 75 to 83)
normal subgroup, where there were 18 women and two
men. In this age group, the majority of excluded subjects
were excluded because of the presence of known cardiovas-
cular disease (72% of women excluded, 84% of men ex-
cluded) and a minority were excluded purely on the basis of
diastolic dysfunction (10% of women excluded, 7% of men
excluded).
Medical record review. All Olmsted County care provid-
ers have maintained a unified medical record, which is
indexed by the Rochester Epidemiology Project. Each
subject’s medical record was reviewed by trained nurse
chart abstractors using established criteria for hyperten-
sion (12), myocardial infarction (13), and congestive
heart failure (10). Clinical diagnoses of coronary artery
disease, obstructive lung disease, renal failure, and dia-
betes were recorded. Medication questionnaires were
completed by each subject.
Doppler echocardiography. All echocardiograms were
performed by one of three registered diagnostic cardiac
sonographers with the same echocardiographic instrument
(HP-2500) according to protocol and interpreted by a single
echocardiologist (M. M. R.). Two-dimensional and color
Doppler imaging were performed to screen for valvular
stenosis or regurgitation.
In each subject, measurement of EF by M-mode (mod-
ified Quinnones formula), quantitative 2-D (BiPlane Simp-
sons) and semiquantitative 2-D (visual estimate) methods
was attempted as previously described (14–17). For analysis
in the normal subgroup, subjects had normal EF (40%) by
all three methods. For analysis in the entire population, the
visual estimation of EF was used.
Pulsed-wave Doppler examination of mitral (before and
with Valsalva maneuver) and pulmonary venous inflow as
well as Doppler tissue imaging of the mitral annulus was
performed in each subject. Diastolic function was catego-
rized as normal, impaired relaxation without evidence of
increased filling pressures (“impaired relaxation”), impaired
relaxation associated with moderate elevation of filling
pressures (“pseudonormal filling”), and advanced reduction
in compliance (“restrictive filling”), as previously described
(18–21). Decreases in the ratio of the mitral early to late
filling velocities (E/A ratio) indicate a reduction in early
diastolic filling related to impairment of LV relaxation. We
defined impaired relaxation as an E/A ratio 0.75, reflect-
ing the average lower confidence interval for the E/A ratio
in subjects aged45 years in a previous normal cohort (22).
Doppler indices used to discriminate pseudonormal or
restrictive from normal are independent of age.
Left ventricular dimension and mass (M-mode) and left
atrial volume (2-D) were indexed to body surface area.
BNP analysis. Blood for BNP was collected in the fasting
state in ethylenediaminetetraacetic acid-treated tubes and
placed on ice. After centrifugation at 2,500 rpm and 3°C,
the plasma was stored at 80°C.
Plasma BNP was determined by immunoradiometric
assay (nonextracted) using antibody to human BNP
(Shionogi Co. Ltd., Tokyo, Japan), as previously described
(23). The intra-assay (within-day) and interassay (total)
Table 1. Plasma BNP (Biosite [BNP-B] and Shionogi [BNP-S] Assays) by Age and Gender in Normal Subjects
Gender
BNP











Biosite 180 18 (10, 32) 135 27 (15, 43) 56 29 (19, 52) 17 67 (28, 89)
Shionogi 194 28 (13, 55) 141 32 (18, 68) 59 45 (20, 111) 18 58 (26, 172)
Men
Biosite 181 7 (3, 13) 111 11 (5, 20) 40 18 (7, 37) 2 21 (17, 24)
Shionogi 193 17 (9, 34) 118 31 (14, 49) 42 28 (10, 58) 2 38 (31, 44)
The median 25th and 75th percentiles are shown.
BNP  brain natriuretic peptide.
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CHF  congestive heart failure
CI  confidence interval
E/A  early-to-late filling velocities
EF  ejection fraction
HRT  hormone replacement therapy
LV  left ventricular
ROC  receiver operating characteristic
2-D  two-dimensional
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coefficients of variation were both 8% and were consistent
across concentrations of BNP.
One-milliliter aliquots of frozen plasma were shipped to
Biosite Diagnostics (San Diego, California), and the non-
extracted samples were batch-analyzed by a fluorescence
immunoassay (5,24). The within-day coefficient of variation
(9.4% to 15.2%) and total coefficient of variation (10.1% to
16.2%) increased from low to high BNP.
Statistical methods. Because the variability of BNP in-
creased with its mean level, the natural log transformation
was used in the regression analyses to satisfy modeling
assumptions. Nomograms based on age and gender were
established using the least-squares regression fit of log-
transformed BNP with age and gender as predictor vari-
ables. From the fitted model, the 5th, 25th, 50th, 75th, and
95th percentiles were estimated and back-transformed to
the natural scale. An interaction term with age and gender
was also evaluated to determine if the association of age with
BNP differed between the genders.
Unadjusted and adjusted associations of BNP were eval-
uated using Spearman’s correlation coefficient and linear
least-squares regression, respectively. For adjusted associa-
tions, a model with age and gender was fit and, in turn,
variables were added to see if there was significant residual
association that could be explained by these characteristics.
The ability of BNP to detect an EF 40% was evaluated
using receiver operating characteristic (ROC) curves within
age/gender-specific strata. The optimal discriminatory value
was identified as the BNP value that had a combined
sensitivity/specificity at the smallest distance to 100%/
100%, respectively (23).
RESULTS
The association of BNP with age and gender in the
normal subgroup (n  767). The distribution of the
normal subgroup by age/gender and corresponding BNP is
shown in Table 1. Adjusting for age, BNP was higher in
women than men and increased with age within each
gender. Plasma BNP was 32% higher in women than men
(confidence interval [CI]  15% to 51%, p  0.001) by
Shionogi assay and 80% higher by Biosite assay (CI  50%
to 116%, p  0.001). Nomograms for BNP as a function of
age, gender, and assay are reported (Fig. 1). The age/
gender-specific reference ranges (5th and 95th percentile)
for each assay as derived from the regression fit are provided
in Table 2. The association between gender and BNP
remained similar across all age ranges for both assays (p 
0.90).
We sought to determine if age/gender-related changes in
BNP were due to age- or gender-related changes in clinical
Figure 1. Plasma brain natriuretic peptide (BNP) concentration as a function of age for each gender and assay system. The nomogram demonstrates the
5th, 25th, 50th, 75th, and 95th percentiles for BNP according to age.
Table 2. Age and Gender-Specific Ranges (5th–95th
Percentiles) for Plasma BNP (pg/ml) (Biosite and Shionogi
Assays) Derived From the Regression Analysis in Normal
Subjects
Gender BNP Age 45–54 Age 55–64 Age 65–74 Age 75–83
Women
Biosite 8–73 10–93 13–120 16–155
Shionogi 7–157 9–192 11–233 13–284
Men
Biosite 4–40 5–52 7–67 9–86
Shionogi 6–120 7–146 8–177 10–216
BNP  brain natriuretic peptide.
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factors, renal function, or cardiac structural parameters.
Table 3 displays the variables considered as potentially
associated with BNP. Several of these parameters were
associated with BNP but were also associated with age
and/or gender, as indicated in Table 3. Only age, gender,
and left atrial volume index were independently associated
with BNP (Table 4). Within each gender and assay group,
BNP increased according to left atrial volume index.
To further evaluate the association between gender and
BNP, we determined whether BNP was different in the
presence or absence of hormone replacement therapy
(HRT). As measured by the Biosite assay, there was a
relationship between HRT and BNP among women. Of the
388 women in the normal subgroup, 186 (48%) were taking
HRT. Controlling for age, BNP was 21% higher in women
on HRT than in women not on HRT (CI 6% to 40%, p 
0.005) (Fig. 2). Plasma BNP was 99% higher in women on
HRT than in men (CI 75% to 125%, p  0.005) and was
64% higher in women not on HRT than in men (CI 44% to
85%, p  0.005). Similar trends were observed with the
Shionogi assay, but the difference in BNP between women
with or without HRT was not significant (data not shown).
Discriminatory values of BNP for the detection of sys-
tolic dysfunction in the entire cohort (n  2,042). Figure
3 displays the ROC curves for the detection of an EF40%
within each age stratum by gender and assay. Forty subjects
(eight women) had an EF 40%. On each curve, both the
BNP representing the upper (95th percentile) reference
limit, as derived from the regression fit, and the BNP
representing the optimal point on the ROC curve are
indicated. The values for the BNP at the upper reference
limit and at the optimal point on the ROC curve, and the
corresponding sensitivity and specificity for the detection of
an EF 40%, are shown in Table 5. The areas under the
ROC curves were similar within each age/gender stratum
for each assay. However, in general the optimal discrimina-
tory value for BNP increases with age and is higher in
women. Only eight female subjects had an EF 40% and
this significantly limited the power to demonstrate age/
gender differences in the optimal discriminatory value for
BNP. The available data in women are included to demon-
strate the effect on specificity of age/gender-specific parti-
tion values derived from the reference population.
DISCUSSION
In this population-based study, BNP increased with age and
was higher in women than men in a subgroup of subjects
without known cardiovascular disease or detectable struc-
tural heart disease. These associations were not explained by
age- or gender-related changes in blood pressure, renal
function, or cardiac structure. The association of female
gender and BNP appears to be in part related to estrogen
status, as BNP levels were higher in women using HRT.
Although the absolute value of BNP varied between the two
assays, the associations with age and gender were consistent
between assays. In addition, the BNP with optimal sensi-
tivity and specificity for the detection of systolic dysfunction
in the entire population increased with age and was higher
in women, underscoring the clinical relevance of the rela-
tionship among age, gender, and BNP.
Plasma BNP in the normal subgroup. The mechanisms
whereby age influences BNP are unclear. Previous studies
have reported that levels of natriuretic peptides are higher in
Table 3. Variables Examined for Association With Age, Gender, and Plasma BNP Concentration in Normal Subjects
Age Gender Log of Shionogi BNP Log of Biosite BNP
Spearman CC p Value Spearman CC p Value Spearman CC p Value Spearman CC p Value
Age NA NA 0.134 0.0002 0.173  0.0001 0.283  0.0001
Gender 0.134 0.0002 NA NA 0.183  0.0001 0.421  0.0001
Body surface area 0.198  0.0001 0.705  0.0001 0.147  0.0001 0.345  0.0001
Systolic blood pressure 0.255  0.0001 0.080 0.0274 0.021 0.5531 0.006 0.8773
Diastolic blood pressure 0.023 0.5198 0.339  0.0001 0.088 0.0152 0.186  0.0001
Creatinine 0.000 0.9894 0.682  0.0001 0.111 0.0026 0.232 0.0001
Creatinine clearance 0.510  0.0001 0.454  0.0001 0.193  0.0001 0.369  0.0001
LV dimension index 0.079 0.0426 0.449  0.0001 0.134 0.0006 0.263  0.0001
LV mass index 0.047 0.2265 0.325  0.0001 0.003 0.9371 0.150 0.0002
LA volume index 0.006 0.8790 0.131 0.004 0.139 0.0002 0.096 0.0118
BNP  brain natriuretic peptide; CC  correlation coefficient; LA  left atrial; LV  left ventricle; NA  not appropriate.
Table 4. Parameters Independently Associated With BNP









Age 0.020 0.004  0.0001 0.024 0.003  0.0001
Female gender 0.294 0.069  0.0001 0.632 0.053  0.0001
LA volume index 0.029 0.006  0.0001 0.024 0.005  0.0001
Regression coefficients indicate effect per year of age or per ml/m2 for LA volume index.
BNP  brain natriuretic peptide; LA  left atrial.
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the elderly, but did not exclude those with altered cardiac
structure or function (7,9). These investigators suggested
that age-related changes in diastolic dysfunction influence
BNP. However, in the current study subjects with diastolic
dysfunction and the diseases that cause it were excluded.
Although age-related alterations in renal function could
alter BNP, the effect of age was independent of renal
function. The atria and ventricles are sites of BNP produc-
tion, and age-related changes in cardiac size could influence
BNP. However, the effect of age and gender on BNP was
independent of atrial volume, LV dimension, and LV mass.
These data would suggest that as yet undefined alterations
in BNP production, secretion, or degradation occur with
age, and further studies are needed to elucidate the mech-
anism(s) responsible for this effect. An alternative explana-
tion is that BNP increases in response to age-related
alterations in cardiac structure or function that are not
detectable by current techniques. Such a mechanism re-
mains speculative and not pertinent to current diagnostic
use of BNP, as the prognostic implications of BNP in the
absence of detectable structural heart disease have not been
defined.
The effect of gender on BNP was also remarkable. This
effect was independent of other factors, observed with both
assay systems, and substantial. As gender-related differences
in endothelin and angiotensin-converting enzyme activity
have been reported to be associated with hormonal status
(25,26), we investigated the effect of HRT status on BNP
and found evidence of a relationship between HRT and
BNP. Although preliminary, these data suggest that BNP
production may be sensitive to estrogen regulation and
represent an area for further study.
After adjusting for age and gender, we found a modest
but significant relationship between BNP and left atrial
volume index in the normal subgroup. Thus, in the normal
state, plasma BNP may be related to the size of the gland
that produces it. Although the relationship between BNP
and LV mass was not significant after adjustment for age
and gender, production of BNP by ventricular myocytes is
clearly increased in the presence of hypertrophy. Thus, a
Figure 2. Box plot of plasma brain natriuretic peptide (BNP) concentra-
tions (Biosite assay) according to hormone replacement therapy (HRT)
status as a function of age in female (F) subjects. The box plots indicate the
5th, 25th, 50th, 75th, and 95th percentiles.
Figure 3. Receiver operating curves defining the sensitivity and specificity of brain natriuretic peptide (BNP) (by Shionogi and Biosite assays) for the
detection of systolic dysfunction (ejection fraction 40%) in each age strata of men and women. The open circle indicates the BNP value at the upper
reference limit as derived from the regression fit in each age/gender/assay stratum. The open triangle indicates the BNP value with optimal sensitivity and
specificity (the “optimal point”) on the receiver operating characteristic (ROC) curve.
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stronger relationship between plasma BNP and LV mass or
left atrial volume may be apparent if subjects with cardio-
vascular disease are included.
Implications for use of BNP as a diagnostic test. Previ-
ous studies have reported the sensitivity and specificity of
BNP for the detection of CHF or LV dysfunction (2–5).
These studies derived a single abnormal (partition) value for
BNP by ROC analysis and have not examined the use of
age- or gender-specific partition values. For the Biosite
assay, values of 75 to 80 pg/ml have been reported as
partition values for detection of ventricular dysfunction
(with and without symptoms) or diagnosis of CHF (5,24).
For the Shionogi assay, values of 17.9 to 79 pg/ml have been
reported for detection of ventricular dysfunction or CHF in
highly variable populations (2,8,23,27,28). Although we
found that the area under the ROC curves was similar
among the age/gender strata, the optimal partition value for
the detection of systolic dysfunction differed by assay, age,
and gender.
These data suggest that age-, gender-, and assay-specific
partition values should be used to interpret BNP. The
ultimate partition values used may also depend on the
abnormality being screened for (CHF vs. asymptomatic LV
dysfunction), its severity, the implications of false positives
or negatives and, importantly, on the population being
studied. The operating characteristics of diagnostic tests
may vary according to the population to which they are
applied (11). Even though patients with severe CHF have
very high BNP, age/gender effects still need to be consid-
ered when choosing a partition value. A previous study that
utilized the Biosite assay to measure BNP reported that a
BNP of 80 pg/ml is diagnostic of CHF in symptomatic
patients presenting for urgent care (5). Although the aver-
age BNP value in patients with CHF was very high, and the
performance of the test was outstanding, the study popula-
tion was young (mean age 63 years) and predominately men
(94%). In the current study, a value of 80 pg/ml would be
abnormal in most male age groups (Table 2, Fig. 1) but
would be well within the 95th percentile for women. A
higher partition value may be needed in women or older
patients where use of age- and gender-specific partition
values may enhance the predictive characteristics of the test,
particularly avoiding specificity problems in the elderly.
Limitations. The population of Olmsted County, Minne-
sota, is primarily white, and thus we are unable to investi-
gate potential influence of ethnicity on BNP. Our study was
confined to subjects 44 years of age.
Conclusions. In this population-based cohort, we found
that BNP increases with age and is higher in women among
subjects without cardiovascular disease or cardiac dysfunc-
tion. The magnitude of the effects of age and gender on
BNP in the normal subgroup suggested that both parame-
ters need to be considered when interpreting BNP, and
indeed, the optimal discriminatory value of BNP for the
detection of systolic dysfunction in the population was
higher in women and older persons. Although the ultimate
partition value for BNP used in clinical practice will be
influenced by a number of variables, these data suggest that
age-, gender-, and assay-specific values will be needed.
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